Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision.

European Journal of Clinical Pharmacology
G TrifiròV Arcoraci

Abstract

To assess whether the prescribing pattern of lipid-lowering drugs (LLD) changed after reimbursement criteria revision in a general practice in southern Italy. From the Caserta-1 Local Health Service database, 93 general practitioners (GPs) who had consistently sent data about their patients during the years 2003-2005 were recruited. Prevalence of use and incidence of new treatments were calculated for each year, stratified by three drug cohorts: statins, omega-3 fatty acids, and fibrates. Subanalyses by gender, age, and indication of use were performed. Overall, 1-year prevalence of LLD use increased from 2003 to 2004. After reimbursement criteria revision (November 2004), a slight decrease was observed for statins, from 41.1 (95% CI: 39.9-42.2) per 1,000 inhabitants in 2004 to 40.3 (39.2-41.5) in 2005, while omega-3 utilization fell markedly: 14.6 (13.9-15.3) vs. 5.4 (5.0-5.8). The use of both statins and omega-3 fatty acids was reduced particularly for primary prevention. On the other hand, utilization of statins increased in diabetic patients and as secondary prevention from 2004 to 2005. Concerning individual molecules, 1-year prevalence of use of any statin declined from 2004 to 2005, except for rosuvastatin. Revision of r...Continue Reading

References

Jul 23, 1997·JAMA : the Journal of the American Medical Association·P R HebertC H Hennekens
Oct 21, 1999·Journal of Public Health Medicine·R LawrensonR Farmer
Dec 28, 1999·JAMA : the Journal of the American Medical Association·J C LaRosaS Vupputuri
Jan 10, 2002·Journal of Clinical Epidemiology·Isabelle Savoie, Arminée Kazanjian
Oct 11, 2003·BMJ : British Medical Journal·Giselle Jones
Dec 13, 2003·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Philippe AutierAndré-Robert Grivegnée
Jan 3, 2004·BMJ : British Medical Journal·Jehangir N DinAndrew D Flapan
Apr 21, 2004·Annals of Internal Medicine·Sandeep VijanUNKNOWN American College of Physicians
Apr 22, 2004·JAMA : the Journal of the American Medical Association·Dennis T KoDavid A Alter
Jun 17, 2004·Circulation·Stefano BellostaAlberto Corsini
Nov 3, 2004·Lancet·Stefan R FlorentinusAnthonius de Boer
Jan 22, 2005·International Journal of Epidemiology·Marco FerrarioUNKNOWN CUORE Project Research Group
Apr 13, 2005·Atherosclerosis. Supplements·Lawrence A Leiter
Jul 27, 2005·European Journal of Clinical Pharmacology·Nadia PiacentiniUNKNOWN UVEC group
Oct 21, 2005·British Journal of Clinical Pharmacology·T WalleyE Van Ganse
Jan 4, 2007·European Journal of Clinical Pharmacology·Paola DeambrosisAlessandro Chinellato
Mar 24, 2007·European Journal of Clinical Pharmacology·Anita KozyrskyjAmber Racher

❮ Previous
Next ❯

Citations

Mar 10, 2010·Wiener klinische Wochenschrift·Wolfgang C WinkelmayerUNKNOWN Pharmacoeconomics Advisory Council of the Austrian Sickness Funds
Feb 24, 2010·Journal of Clinical Pharmacy and Therapeutics·V Maio, J J Gagne
Jan 6, 2015·British Journal of Clinical Pharmacology·Domenico ItalianoVincenzo Arcoraci
Aug 5, 2015·The Cochrane Database of Systematic Reviews·Arash RashidianAndrew D Oxman
Oct 4, 2014·International Journal of Immunopathology and Pharmacology·V ArcoraciM Tari
Mar 21, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.